FDA Approval of Cresnessity Signals Breakthrough for Rare Endocrine Disorder
For over 70 years, patients with classic congenital adrenal hyperplasia (CAH) have had limited treatment options—options that often come with debilitating side effects. However, a new chapter begins with the recent FDA approval of Neurocrine Biosciences’ Crenessity, the first non-steroidal treatment for CAH. This decision heralds a groundbreaking shift in the management of this rare […]
FDA Approval of Cresnessity Signals Breakthrough for Rare Endocrine Disorder Read More »